AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women wi… Read more
AMGN (AMGN) - Total Assets
Latest total assets as of December 2025: CA$90.59 Billion CAD
Based on the latest financial reports, AMGN (AMGN) holds total assets worth CA$90.59 Billion CAD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
AMGN - Total Assets Trend (2022–2025)
This chart illustrates how AMGN’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
AMGN - Asset Composition Analysis
Current Asset Composition (December 2025)
AMGN's total assets of CA$90.59 Billion consist of 32.1% current assets and 67.9% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 10.1% |
| Accounts Receivable | CA$9.57 Billion | 10.6% |
| Inventory | CA$6.22 Billion | 6.9% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$22.28 Billion | 24.6% |
| Goodwill | CA$18.68 Billion | 20.6% |
Asset Composition Trend (2022–2025)
This chart illustrates how AMGN's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AMGN's current assets represent 32.1% of total assets in 2025, a decrease from 34.1% in 2022.
- Cash Position: Cash and equivalents constituted 10.1% of total assets in 2025, down from 11.7% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 44.0% of total assets, a decrease from 47.0% in 2022.
- Asset Diversification: The largest asset category is intangible assets at 24.6% of total assets.
AMGN Competitors by Total Assets
Key competitors of AMGN based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367
|
China | CN¥1.52 Billion |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
|
China | CN¥13.11 Billion |
|
Guangdong Jiaying Pharmaceutical Co Ltd
SHE:002198
|
China | CN¥774.73 Million |
|
PharmGen Science Inc
KO:004720
|
Korea | ₩331.46 Billion |
AMGN - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - AMGN generates 0.41x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, AMGN generates $8.51 in net profit.
AMGN - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.14 | 1.26 | 1.26 |
| Quick Ratio | 0.90 | 0.95 | 0.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$3.57 Billion | CA$ 5.93 Billion | CA$ 5.93 Billion |
AMGN - Advanced Valuation Insights
This section examines the relationship between AMGN's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 22.80 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | -1.4% |
| Total Assets | CA$90.59 Billion |
| Market Capitalization | $10.56 Billion USD |
Valuation Analysis
Below Book Valuation: The market values AMGN's assets below their book value (0.12 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: AMGN's assets decreased by 1.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for AMGN (2022–2025)
The table below shows the annual total assets of AMGN from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CA$90.59 Billion | -1.36% |
| 2024-12-31 | CA$91.84 Billion | -5.47% |
| 2023-12-31 | CA$97.15 Billion | +49.19% |
| 2022-12-31 | CA$65.12 Billion | -- |